As its biotechs hit the pandemic exit, Longitude raises $585M for new neuro, cancer, aging and orphan-focused fund
The years have been kind to Longitude Capital. This year, too.
A 2006 spinout of Pequot Capital, its founders started their new firm just four years before the parent company would go under amid insider trading allegations. Their first life sciences fund raised $325 million amid the financial crisis, they added a second for $385 million and then in, 2016, a third for $525 million. In the last few months, the pandemic biotech IPO boom netted several high-value exits from those funds, as Checkmate, Vaxcyte, Inozyme and Poseida all went public.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.